2017
Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings
Antillón M, Bilcke J, Paltiel AD, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine 2017, 35: 3506-3514. PMID: 28527687, PMCID: PMC5462484, DOI: 10.1016/j.vaccine.2017.05.001.Peer-Reviewed Original ResearchConceptsRoutine infant vaccinationCost-effectiveness analysisOptimal strategyHealthcare payer perspectiveVaccine priceOne-time catchMiddle-income countriesIntervention costsPayer perspectiveInfant vaccinationDong ThapRoutine vaccinationMiddle-income settingsTyphoid transmissionRate of hospitalizationNumber of dosesDynamic modelPricesWorld Health OrganizationInvestmentLwakReturnWillingnessTyphoid feverVaccination
2011
Dengue vector control strategies in an urban setting: an economic modelling assessment
Luz PM, Vanni T, Medlock J, Paltiel AD, Galvani AP. Dengue vector control strategies in an urban setting: an economic modelling assessment. The Lancet 2011, 377: 1673-1680. PMID: 21546076, PMCID: PMC3409589, DOI: 10.1016/s0140-6736(11)60246-8.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioHerd immunityAdult controlsDengue burdenIncremental cost-effectiveness ratioDengue transmissionCost-effective interventionResource-constrained countriesProbabilistic sensitivity analysesCost-effectiveness analysisIncidence of dengueFuture dengue epidemicsImmunological effectsHealth burdenRisk of dengueVector control policiesDengue epidemicsImmunityVector control strategiesBurdenDengueAdult mosquitoesInterventionEpidemicYears
2003
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection
Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR, Kimmel AD, Walensky RP, Sax PE, Freedberg KA. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. The American Journal Of Medicine 2003, 115: 632-641. PMID: 14656616, DOI: 10.1016/j.amjmed.2003.07.007.Peer-Reviewed Original ResearchConceptsQuality-adjusted life expectancyHuman immunodeficiency virus (HIV) infectionClinical trial cohortImmunodeficiency virus infectionAdvanced diseaseCost-effectiveness ratioAdherence interventionsAntiretroviral therapyTrial cohortEarly diseaseVirus infectionUrban cohortLife expectancyHIV ribonucleic acid levelsEffective adherence interventionsCD4 cell countCombination antiretroviral therapyVirologic failure ratesLow baseline levelsFailure rateRibonucleic acid levelsStandard careHIV infectionHealthy patientsClinical trials